Grifols, S.A. (NASDAQ:GRFS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been given a consensus recommendation of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.30.

A number of equities research analysts recently weighed in on GRFS shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a report on Tuesday, August 5th. Zacks Research lowered Grifols from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th.

Hedge Funds Weigh In On Grifols

Several large investors have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Grifols by 2.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 1,114 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Grifols by 39.5% in the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,584 shares in the last quarter. Merit Financial Group LLC grew its position in shares of Grifols by 14.1% in the 3rd quarter. Merit Financial Group LLC now owns 13,978 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 1,728 shares in the last quarter. Savant Capital LLC increased its holdings in shares of Grifols by 16.0% in the 3rd quarter. Savant Capital LLC now owns 14,011 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 1,935 shares during the last quarter. Finally, Ascent Group LLC raised its position in shares of Grifols by 12.5% during the 3rd quarter. Ascent Group LLC now owns 17,597 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 1,951 shares in the last quarter.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $8.40 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14. The business has a 50-day moving average of $9.35 and a 200-day moving average of $9.33. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of 44.21, a PEG ratio of 0.32 and a beta of 0.69.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.